The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Portrait of Sophia Zackrisson. Photo

Sophia Zackrisson

Research group manager, Principal investigator, Professor, MD

Portrait of Sophia Zackrisson. Photo

False-positive recalls in the prospective Malmö Breast Tomosynthesis Screening Trial

Author

  • Kristin Johnson
  • Jakob Olinder
  • Aldana Rosso
  • Ingvar Andersson
  • Kristina Lång
  • Sophia Zackrisson

Summary, in English

Objectives: To evaluate the total number of false-positive recalls, including radiographic appearances and false-positive biopsies, in the Malmö Breast Tomosynthesis Screening Trial (MBTST). Methods: The prospective, population-based MBTST, with 14,848 participating women, was designed to compare one-view digital breast tomosynthesis (DBT) to two-view digital mammography (DM) in breast cancer screening. False-positive recall rates, radiographic appearances, and biopsy rates were analyzed. Comparisons were made between DBT, DM, and DBT + DM, both in total and in trial year 1 compared to trial years 2 to 5, with numbers, percentages, and 95% confidence intervals (CI). Results: The false-positive recall rate was higher with DBT, 1.6% (95% CI 1.4; 1.8), compared to screening with DM, 0.8% (95% CI 0.7; 1.0). The proportion of the radiographic appearance of stellate distortion was 37.3% (91/244) with DBT, compared to 24.0% (29/121) with DM. The false-positive recall rate with DBT during trial year 1 was 2.6% (95% CI 1.8; 3.5), then stabilized at 1.5% (95% CI 1.3; 1.8) during trial years 2 to 5. The percentage of stellate distortion with DBT was 50% (19/38) trial year 1 compared to 35.0% (72/206) trial years 2 to 5. Conclusions: The higher false-positive recall rate with DBT compared to DM was mainly due to an increased detection of stellate findings. The proportion of these findings, as well as the DBT false-positive recall rate, was reduced after the first trial year. Clinical relevance statement: Assessment of false-positive recalls gives information on potential benefits and side effects in DBT screening. Key Points: • The false-positive recall rate in a prospective digital breast tomosynthesis screening trial was higher compared to digital mammography, but still low compared to other trials. • The higher false-positive recall rate with digital breast tomosynthesis was mainly due to an increased detection of stellate findings; the proportion of these findings was reduced after the first trial year.

Department/s

  • LUCC: Lund University Cancer Centre
  • Radiology Diagnostics, Malmö
  • Geriatrics
  • EpiHealth: Epidemiology for Health
  • eSSENCE: The e-Science Collaboration
  • LU Profile Area: Light and Materials
  • LTH Profile Area: Photon Science and Technology

Publishing year

2023

Language

English

Pages

8089-8099

Publication/Series

European Radiology

Volume

33

Issue

11

Document type

Journal article

Publisher

Springer

Topic

  • Cancer and Oncology

Keywords

  • Breast neoplasm
  • Female
  • Mammography
  • Mass screening

Status

Published

Research group

  • Radiology Diagnostics, Malmö
  • Geriatrics

ISBN/ISSN/Other

  • ISSN: 0938-7994